Mostrar el registro sencillo del ítem

dc.contributor.authorMartinón Torres, Federico 
dc.contributor.authorBosch, X.
dc.contributor.authorRappuoli, R.
dc.contributor.authorLadhani, S.
dc.contributor.authorRedondo, E.
dc.contributor.authorVesikari, T.
dc.contributor.authorGarcia-Sastre, A.
dc.contributor.authorRivero-Calle, I.
dc.contributor.authorGomez-Rial, J.
dc.contributor.authorSalas, A.
dc.contributor.authorMartin, C.
dc.contributor.authorFinn, A.
dc.contributor.authorButler, R.
dc.date.accessioned2021-11-18T10:51:13Z
dc.date.available2021-11-18T10:51:13Z
dc.date.issued2019
dc.identifier.issn2164-5515
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816368/pdf/khvi-15-10-1609823.pdfes
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31158041es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15682
dc.description.abstractThe Ninth Interactive Infectious Disease workshop TIPICO was held on November 22-23, 2018, in Santiago de Compostela, Spain. This 2-day academic experience addressed current and topical issues in the field of infectious diseases and vaccination. Summary findings of the meeting include: cervical cancer elimination will be possible in the future, thanks to the implementation of global vaccination action plans in combination with appropriate screening interventions. The introduction of appropriate immunization programs is key to maintain the success of current effective vaccines such as those against meningococcal disease or rotavirus infection. Additionally, reduced dose schedules might improve the efficiency of some vaccines (i.e., PCV13). New vaccines to improve current preventive alternatives are under development (e.g., against tuberculosis or influenza virus), while others to protect against infectious diseases with no current available vaccines (e.g., enterovirus, parechovirus and flaviviruses) need to be developed. Vaccinomics will be fundamental in this process, while infectomics will allow the application of precision medicine. Further research is also required to understand the impact of heterologous vaccine effects. Finally, vaccination requires education at all levels (individuals, community, healthcare professionals) to ensure its success by helping to overcome major barriers such as vaccine hesitancy and false contraindications.en
dc.language.isoenges
dc.subject.meshClinical Trials as Topic*
dc.subject.meshCongresses as Topic*
dc.subject.meshHumans*
dc.subject.meshCommunicable Diseases*
dc.subject.meshVaccines*
dc.titleTIPICO IX: report of the 9(th) interactive infectious disease workshop on infectious diseases and vaccinesen
dc.typeArtigoes
dc.authorsophosMartinon-Torres, F.
dc.authorsophosBosch, X.
dc.authorsophosRappuoli, R.
dc.authorsophosLadhani, S.
dc.authorsophosRedondo, E.
dc.authorsophosVesikari, T.
dc.authorsophosGarcia-Sastre, A.
dc.authorsophosRivero-Calle, I.
dc.authorsophosGomez-Rial, J.
dc.authorsophosSalas, A.
dc.authorsophosMartin, C.
dc.authorsophosFinn, A.
dc.authorsophosButler, R.
dc.identifier.doi10.1080/21645515.2019.1609823
dc.identifier.pmid31158041
dc.identifier.sophos31343
dc.issue.number10es
dc.journal.titleHuman Vaccines & Immunotherapeutics es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatríaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial2405es
dc.page.final2415es
dc.rights.accessRightsembargoedAccesses
dc.subject.decscongresos como asunto*
dc.subject.decsensayos clínicos como asunto*
dc.subject.decsenfermedades transmisibles*
dc.subject.decsvacunas*
dc.subject.decshumanos*
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number15es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem